Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03175224 · ClinicalTrials.gov registry record · Phase 2

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

A Phase 2 study of Lung Cancer and Gastric Cancer, sponsored by Apollomics.

Recruiting
Registry status
Phase 2
Development phase
497
Enrollment target
20
Study locations

NCT03175224 is a Phase 2 study of Lung Cancer and Gastric Cancer that is actively recruiting participants, run by Apollomics. The registered enrollment target is 497 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03175224, a Phase 2 study of Lung Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Apollomics.

RECRUITING
Registry status
Phase 2
Development phase
497 participants
Enrollment target
20
Study locations

Study Summary

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)

Conditions Studied

Lung Cancer Gastric Cancer Solid Tumors Advanced Cancer Glioblastoma Multiforme NSCLC Brain Tumor Gastroesophageal Junction Adenocarcinoma Renal Cancer EGFR Gene Mutation

Interventions

  • DRUG APL-101 Oral Capsules

Study Locations (20)

Other

  • St Vincents Hospital Melbourne - Melbourne
  • Cross Cancer Institute - Edmonton
  • McGill University Health Center - Research Institute - Montreal
  • Princess Margaret Hospital - Toronto
  • Cancer Care Manitoba - Winnipeg
  • CHRU de Brest - Hôpital Morvan - Brest
  • Centre Leon Berard - Lyon
  • Centre d'Essais Precoces en Cancerologie de Marseille - Marseille
  • Hopital Bichat - Claude Bernard - AP-HP - Paris
  • Gustave Roussy - Villejuif
  • Orszagos Koranyi Pulmonologiai Intezet - Budapest
  • Komarom-Esztergom Varmegyei Szent Borbala Korhaz - Tatabánya
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola - Bologna
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - Meldola

California

  • Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute - Los Angeles

Florida

  • Moffitt - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

North Carolina

  • University of North Carolina - Chapel Hill

Pennsylvania

  • Penn State Milton S. Hershey Medical Center - Hershey

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 497 participants
Start Date 2017-09-27
Est. Completion 2026-11-30
Phase Phase 2

Sponsor

Apollomics

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03175224

The ClinicalTrials.gov registry entry for NCT03175224 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Apollomics, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which APL-101 Oral Capsules is the first listed.

NCT03175224 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03175224 about?

NCT03175224 is a clinical study titled "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors". To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w...

What is the current status of trial NCT03175224?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 497 participants. The study started on 2017-09-27. Estimated completion is 2026-11-30.

What conditions does trial NCT03175224 study?

This clinical trial studies the following conditions: Lung Cancer, Gastric Cancer, Solid Tumors, Advanced Cancer, Glioblastoma Multiforme.

What interventions are being tested in trial NCT03175224?

The interventions under investigation include: APL-101 Oral Capsules (DRUG).

Who is sponsoring clinical trial NCT03175224?

This trial is sponsored by Apollomics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03175224 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.